This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D80.5 | Synonyms: Hyper-IgM syndrome, HIGM, CD40L deficiency, CD40 deficiency, AID deficiency
Hyper-IgM syndrome was first described in the early 1960s in a group of pediatric patients with recurrent infections, high serum IgM, and IgG and IgA deficiency. Rosen and colleagues (1961) and Burtin and colleagues (1965) each reported this unusual pattern of immunodeficiency, describing it with the term "dysgammaglobulinemia."
In 1993, Aruffo and colleagues and DiSanto and colleagues independently discovered that the cause of X-linked Hyper-IgM syndrome (XHIM) is mutation of the CD40 ligand (CD40L, CD154, TNFSF5) gene. This was a landmark discovery showing that contact-dependent interaction between T cells and B cells is essential for isotype switching.
Subsequently, as various molecular defects were identified, including CD40 (TNFRSF5) deficiency (1995), activation-induced cytidine deaminase (AID, AICDA) deficiency (2000), and uracil-DNA glycosylase (UNG) deficiency (2000), Hyper-IgM syndrome began to be recognized not as a single disease but as a heterogeneous group of immunodeficiencies.
In Korea, patients with Hyper-IgM syndrome, including CD40L deficiency, began to be reported after the 2000s, when the rare disease registration system was established. Cases of successful treatment through hematopoietic stem cell transplantation (HSCT) have been published by a small number of specialized medical institutions in Korea.
Hyper-IgM syndrome is classified into five or more types caused by the following molecular defects:
| Type | Mode of inheritance | Defective gene | Features |
|---|---|---|---|
| HIGM1 | X-linked recessive | CD40L (TNFSF5, Xq26.3) | Most common (more than 70% of all cases), with opportunistic infections |
| HIGM2 | Autosomal recessive | AID (AICDA, 12p13) | Lymphadenopathy, opportunistic infections rare |
| HIGM3 | Autosomal recessive | CD40 (TNFRSF5, 20q13.12) | Clinical features similar to HIGM1 |
| HIGM4 | Autosomal recessive | UNG (12q24.1) | Very rare |
| HIGM5 | X-linked | NEMO (IKBKG, Xq28) | May be accompanied by anhidrosis |
When CD40L on activated CD4+ T cells binds CD40 on B cells, an isotype switching signal is transmitted. When this signal is blocked, B cells cannot perform class switching to IgG, IgA, or IgE and secrete only IgM.
HIGM1 is inherited in an X-linked recessive manner and is fully expressed only in males. The CD40L gene is located at Xq26.3, and various mutation types have been reported, including point mutations, deletions, and frameshift mutations. Carrier females (heterozygotes) have no clinical symptoms but can transmit it to their children.
AID, CD40, and UNG deficiencies are inherited in an autosomal recessive manner, and males and females can be affected equally. When both parents are carriers (heterozygotes), each child has a 25% risk of being affected. Frequency may be higher in populations with frequent consanguineous marriage.
Sanger sequencing of the CD40L gene is the standard diagnostic method for HIGM1. Testing of the AICDA, CD40, and UNG genes is also performed when clinically suspected. These genes are included in primary immunodeficiency NGS panels.
The prevalence of HIGM1 (X-linked CD40L deficiency) is estimated at about 1~3 per 1 million male births. All Hyper-IgM syndromes together account for about 2~5% of primary immunodeficiencies.
HIGM1 affects only males, and in most cases symptoms appear as recurrent infections within the first 1~2 years of life. HIGM2 (AID deficiency) affects males and females equally, and its clinical features tend to be milder than those of HIGM1. HIGM3 (CD40 deficiency) is very rare, with only a few dozen cases reported worldwide.
In Korea, based on Health Insurance Review & Assessment Service (HIRA) data, a few dozen patients with the D80.5 code are registered each year. Cases of treatment through HSCT have been reported at specialized medical institutions such as Severance Hospital and Asan Medical Center, and early genetic diagnosis and transplantation are improving the prognosis.
In a normal immune response, after antigen stimulation B cells initially produce IgM and then, with T cell help (CD40-CD40L interaction and cytokines), perform isotype switching to IgG, IgA, and IgE. In CD40L or CD40 deficiency, this switching signal is blocked, so B cells continue to produce only IgM. As a result, serum IgM is normal to elevated, and IgG, IgA, and IgE are markedly reduced.
The CD40-CD40L interaction is also essential for the activation of macrophages and dendritic cells. Therefore, patients with HIGM1 have T cell-mediated immune defects in addition to simple antibody deficiency. In particular, defense against Pneumocystis jirovecii, Cryptosporidium, and Toxoplasma is impaired, and opportunistic infections by these pathogens characteristically occur.
Neutropenia occurs in about 50% of patients with HIGM1 and is presumed to be due to anti-neutrophil autoantibodies or impaired bone marrow maturation. Neutropenia greatly increases the risk of oral ulcers and bacterial sepsis.
Recurrent bacterial infections begin to appear after 6~12 months of age as maternal antibodies wane. Recurrent pneumonia, sinusitis, otitis media, and oral ulcers are the main initial symptoms.
The characteristic manifestation of HIGM1 is Pneumocystis jirovecii pneumonia (PCP), which can occur within the first 6 months of life. Chronic diarrhea and sclerosing cholangitis caused by Cryptosporidium are fatal complications and one of the main causes of death in HIGM1. Opportunistic infections by CMV and Toxoplasma also occur.
Recurrent oral ulcers (aphthous ulcers), gingivitis, and skin abscesses are symptoms related to neutropenia. During periods of severe neutropenia, the risk of bacterial sepsis is very high.
Patients with AID deficiency (HIGM2) generally have few invasive opportunistic infections, and lymph node and tonsillar enlargement and autoimmune phenomena are more prominent. CD40 deficiency (HIGM3) is similar to HIGM1 but rarer.
Growth failure, lymphadenopathy (particularly HIGM2), hepatosplenomegaly, and tonsillar enlargement are observed. Oral aphthous ulcers are characteristic. With PCP infection, hypoxemia, cyanosis, and dyspnea appear.
Serum IgM is normal or markedly elevated (>400 mg/dL), and IgG (generally <200 mg/dL) and IgA are markedly reduced. IgE also tends to be reduced.
The peripheral blood B cell count is normal, but class-switched memory B cells are markedly reduced or absent. T cell counts are generally normal, but when CD40L expression on CD4+ T cells is examined with anti-CD40L antibody, expression is absent or markedly reduced in HIGM1.
The complete blood count shows a reduced absolute neutrophil count (ANC). Recurrent or chronic neutropenia occurs in about 50% of HIGM1.
In children with recurrent bacterial infections or PCP after 6 months of age, quantification of serum immunoglobulins (IgG, IgA, IgM) is performed first. If a pattern of elevated IgM + reduced IgG/IgA is found, CD40L expression testing (flow cytometry) is performed immediately.
Early screening is recommended for male infants with a family history of X-linked Hyper-IgM syndrome. Through genetic counseling, prenatal or early postnatal genetic testing can be performed for the male children of carrier females.
In some countries, abnormalities are sometimes detected in expanded newborn screening that includes T, B, and NK cell counts and immunoglobulin quantification, but newborn screening targeting HIGM alone is not currently standardized.
The pattern of elevated or normal IgM + markedly reduced IgG and IgA is central to the diagnosis. Early in life, IgG may be measured falsely high because of interference from maternal antibodies, so repeat measurement is important.
This is the first-line confirmatory test for HIGM1. CD40L expression is assessed by flow cytometry using anti-CD40L (anti-CD154) antibody on T cells stimulated with PHA or PMA/ionomycin. If expression is absent or markedly reduced, CD40L gene analysis is performed.
Sanger sequencing of the CD40L (TNFSF5) gene is the standard genetic diagnostic method for HIGM1. If negative, analysis of the AICDA, CD40, UNG, and IKBKG genes or primary immunodeficiency NGS panel testing is performed.
Testing for Pneumocystis jirovecii (PCR, bronchoalveolar lavage fluid testing), Cryptosporidium (stool testing, cholangiography), and CMV (PCR) is performed when infection is suspected.
IVIG (intravenous immunoglobulin) or SCIG (subcutaneous immunoglobulin) is given regularly every 3~4 weeks to maintain IgG levels at the target level (serum IgG trough >500~800 mg/dL). This reduces the frequency and severity of bacterial infections.
TMP-SMX (trimethoprim-sulfamethoxazole) is given continuously for prevention of Pneumocystis jirovecii. To prevent Cryptosporidium infection, drinking safe tap water (boiled or filtered water) is emphasized.
G-CSF (granulocyte colony-stimulating factor) is given to increase the neutrophil count, and for severe oral ulcers, topical steroid application and systemic antibiotics are used.
The definitive treatment of HIGM1 (CD40L deficiency) is hematopoietic stem cell transplantation from an HLA-matched donor. Early transplantation (before age 5~10, before Cryptosporidium bile duct damage) gives the best results. Successful transplantation can normalize immune function and prevent opportunistic infections.
Clinical trials of CD40L gene therapy are under way. Lentiviral vector-based CD40L gene correction is being studied at the preclinical and early clinical stages.
Before the HSCT era, the median survival of HIGM1 patients was only into the early 20s because of chronic complications such as Cryptosporidium cholangitis, pulmonary fibrosis, and cirrhosis, and recurrent infections. Survival has been prolonged with IVIG and TMP-SMX prophylaxis.
With successful HLA-matched sibling HSCT, long-term survival reaches 70~80%, and outcomes of unrelated donor transplantation are also improving. If Cryptosporidium bile duct damage is already present at transplantation, biliary complications may persist after transplantation.
Patients with AID deficiency have a lower risk of opportunistic infections and a better prognosis than those with HIGM1. Management of lymphadenopathy and autoimmune phenomena is the main challenge.
Carrier females of X-linked HIGM1 are educated through genetic counseling about the risk when a male child is born. Prenatal diagnosis is possible by fetal genetic testing (CD40L gene analysis) using CVS or amniocentesis.
PCP is prevented with TMP-SMX prophylaxis. To avoid exposure to Cryptosporidium, use of safe water sources, caution when visiting swimming pools, and limiting contact with animals (particularly livestock and ruminants) are recommended.
Live vaccines (BCG, MMR, varicella vaccine) may be dangerous in an immunodeficient state and should be approached cautiously. Pneumococcal, meningococcal, Hib, and influenza (inactivated) vaccines can be given alongside immunoglobulin treatment.